BioAdvance News

QR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease

By WebmasterDecember 1, 2008November 1st, 2024No Comments

QR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease
Read more here

Previous PostBioAdvance Names Dr. Philip P. Gerbino Chair and Elects Dr. John M. Daly to Board of Directors
Next PostTorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma

QR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostBioAdvance Names Dr. Philip P. Gerbino Chair and Elects Dr. John M. Daly to Board of Directors

Next PostTorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma